Bradley Pharmaceuticals
In this article, we will explore the different facets of Bradley Pharmaceuticals and its impact on various aspects of everyday life. From its origins to its relevance today, Bradley Pharmaceuticals has played a crucial role in society and has been the subject of debate and interest. Over the years, Bradley Pharmaceuticals has evolved and found its place in different areas, influencing the way we interact with the world around us. Through a detailed analysis, we will discover the different nuances and perspectives that surround Bradley Pharmaceuticals, thus understanding its importance in our daily lives and its relevance in the contemporary context.
 | |
| Company type | Merged |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1985 |
| Fate | closed February 21, 2008 |
| Successor | Nycomed |
| Headquarters | Fairfield Township, Essex County, New Jersey |
Key people | Daniel Glassman (CEO) |
| Products | Adoxa, Zoderm, Pamine Forte, Kerol |
| Revenue | US$145 million (2006) |
Number of employees | 300 (as of December 31, 2006) |
Bradley Pharmaceuticals was a pharmaceutical company headquartered in Fairfield Township, Essex County, New Jersey. The company was founded in 1985 by Daniel Glassman who was also its CEO.
The company marketed to niche physician specialties in the U.S. and 38 international markets. Bradley Pharmaceuticals comprised Doak Dermatologics, specialized in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
Doak Dermatologics
Doak Dermatologics was the division of Bradley Pharmaceuticals, that marketed products to dermatologists. Its flag products were Zoderm which is a topical anti-acne product. Adoxa (doxycycline) was an antibiotic intended to treat mild to severe acne.
Kenwood Therapeutics
Kenwood was the affiliate brand that worked with therapeutic products. Among the most prescribed ones were Entsol which is a respiratory therapeutic product and Pamine which is intended to treat digestive problems.
Public trading
The company was publicly traded at the NYSE by its code BDY, since May 2003.
Nycomed Merger
Bradley Pharmaceuticals merged with Nycomed, a European company. The merger was completed on February 21, 2008, and Bradley became an integral part of Nycomed.
References
- ^ "Company Overview of Bradley Pharmaceuticals, Inc". Bloomberg Businessweek. September 17, 2014. Archived from the original on June 5, 2010.
- ^ "Fougera which acquired Nycomed)". Archived from the original (PDF) on 11 February 2012. Alt URL